RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 New Treatment Paradigm for HCV and HCV/HIV Coinfection
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 14
SP 25
OP 27
DO 10.1177/1559897715593929
UL http://mdc.sagepub.com/content/15/14/25.abstract
AB New treatment regimens utilizing combinations of protease (nonstructural protein 3-4A [NS3-4A]), nucleotide (NS5B), nonnucleoside (NS5B), and NS5A inhibitors are successfully being used to treat patients with hepatitis C virus coinfected with HIV. Sustained virologic response rates of ≥ 90% are achieved after 12 to 24 weeks in patients with and without cirrhosis who are treatment naïve and experienced. HIV is no longer a predictor of poorer response to hepatitis C virus therapy.